One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences &#8805;10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.

Verburgh, Myrthe L; Wit, Ferdinand W N M; Boyd, Anders; Verboeket, Sebastiaan O; Reiss, Peter; van der Valk, Marc

One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.

Verburgh, Myrthe L; Wit, Ferdinand W N M; Boyd, Anders; Verboeket, Sebastiaan O; Reiss, Peter; van der Valk, Marc.

Afiliação

Verburgh ML; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Wit FWNM; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Boyd A; HIV Monitoring Foundation, Amsterdam, The Netherlands.
Verboeket SO; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Reiss P; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
van der Valk M; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Open Forum Infect Dis ; 9(7): ofac291, 2022 Jul.

Article em En | MEDLINE | ID: mdl-35873291

Palavras-chave

antiretroviral therapy switch; integrase strand transfer inhibitor; metabolic parameters; tenofovir alafenamide; weight gain

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article